Scheper R J, Dalton W S, Grogan T M, Schlosser A, Bellamy W T, Taylor C W, Scuderi P, Spier C
Dept. of Pathology, Free University Hospital, Amsterdam, The Netherlands.
Int J Cancer. 1991 Jun 19;48(4):562-7. doi: 10.1002/ijc.2910480414.
Drug resistance has been associated with resistance to NK- and LAK-cell-mediated cytotoxicity. We evaluated this issue in human cell lines, using multiple myeloma cells (8226) and 2 multi-drug-resistant (MDR) sublines selected using doxorubicin (8226/Dox40) and mitoxantrone (8226/MR40). In parallel, we studied the human breast carcinoma cell line series MCF7, MCF7/D40 and MCF7/Mitox. Unlike the sensitive parental cell lines, all 4 sublines display MDR-patterns of resistance, with the P-glycoprotein pump (P-170) detected only in the doxorubicin-selected sublines. Flow cytometric and immunocytochemical analyses showed expression of cellular adhesion molecules ICAM-I and LFA-3, and MHC-Class-I (MCF7/D40 only), to be decreased in the doxorubicin-selected MDR-sublines, whereas expression of CD56 (Leu 19) was strongly up-regulated in 8226/Dox40. Lysis of P-170-positive MDR tumor cells by NK or LAK cells was, however, unaffected by these alterations, suggesting redundancy in effector:target-cell adhesion pathways. Mitoxantrone-selected tumor cells did not display P-170, nor did they show altered expression of cellular adhesion molecules. Their susceptibility to NK or LAK cytolysis was also unimpaired as compared to the parental cell lines. Clinically, these results imply that immunotherapeutic modalities aiming at increased natural killer functions deserve full consideration even in patients who have become refractory to further cytostatic drug treatment.
耐药性与对自然杀伤细胞(NK)和淋巴因子激活的杀伤细胞(LAK)介导的细胞毒性的抗性有关。我们使用多发性骨髓瘤细胞(8226)以及通过阿霉素(8226/Dox40)和米托蒽醌(8226/MR40)筛选出的2个多药耐药(MDR)亚系,在人细胞系中评估了这一问题。同时,我们研究了人乳腺癌细胞系MCF7、MCF7/D40和MCF7/米托蒽醌。与敏感的亲本细胞系不同,所有4个亚系均表现出MDR模式的抗性,仅在阿霉素筛选的亚系中检测到P-糖蛋白泵(P-170)。流式细胞术和免疫细胞化学分析显示,在阿霉素筛选的MDR亚系中,细胞黏附分子ICAM-1和LFA-3以及MHC-I类分子(仅在MCF7/D40中)的表达降低,而在8226/Dox40中CD56(Leu 19)的表达强烈上调。然而,NK或LAK细胞对P-170阳性MDR肿瘤细胞的杀伤不受这些改变的影响,提示效应细胞与靶细胞黏附途径存在冗余。米托蒽醌筛选的肿瘤细胞未显示P-170,也未表现出细胞黏附分子表达的改变。与亲本细胞系相比,它们对NK或LAK细胞溶解的敏感性也未受损。临床上,这些结果表明,即使在对进一步的细胞抑制药物治疗已产生耐药性的患者中,旨在增强自然杀伤功能的免疫治疗方法也值得充分考虑。